Lane Nick
Department of Surgery, Royal Free and University College Medical School, Pond Street, NW3 2QG London, UK.
J Theor Biol. 2003 Dec 21;225(4):531-40. doi: 10.1016/s0022-5193(03)00304-7.
The quest for therapies based on molecular genetics (pharmacogenomics, DNA microarrays, etc.) drives pharmaceutical research into individual diseases of old age, but has failed to deliver an unequivocal clinical breakthrough. Attempts to treat most age-related diseases using antioxidant supplements have been equally disappointing, despite the clear benefits of a healthy diet. The double-agent theory is a new, unifying synthesis that draws on flaws in three leading theories of ageing. It argues that there is a tradeoff between oxidative stress as a critical redox signal that marshals genetic defences against physiological stress (such as infection) and oxidative stress as a cause of ageing and age-related disease. The stress response and ageing are linked by redox-sensitive transcription factors, such as NFkappaB. Ageing is a function of rising intracellular oxidative stress, rather than chronological time, but this relationship is obscured because free-radical leakage from mitochondria also tends to rise with age. Mitochondrial leakage produces a genetic response which mirrors that following infection, but because mitochondrial leakage is continuous the shift in gene expression is persistent, leading to the chronic inflammation characteristic of old age. Age-related diseases are thus the price we pay for redox control of stress-gene expression. Because the selective pressure favouring the stress response in youth is stronger than that penalising degenerative diseases after reproductive decline, we may be homeostatically refractory to antioxidant supplements that 'swamp' the redox switch. Furthermore, because genetic selection takes place predominantly in the reductive homeostatic environment of youth, alleles associated with age-related diseases are not inherently damaging (they do not inevitably express a negative effect over time), but are simply less effective in the oxidising conditions of old age. Gene therapies for age-related diseases are unlikely to succeed unless oxidative stress can be controlled physiologically, thereby altering the activity and function of potentially hundreds of genes.
对基于分子遗传学的疗法(药物基因组学、DNA微阵列等)的探索推动了针对老年个体疾病的药物研究,但尚未带来明确的临床突破。尽管健康饮食有明显益处,但使用抗氧化剂补充剂治疗大多数与年龄相关疾病的尝试同样令人失望。双因子理论是一种新的统一综合理论,它借鉴了三种主要衰老理论中的缺陷。该理论认为,作为一种关键氧化还原信号的氧化应激在调集针对生理应激(如感染)的遗传防御方面,与作为衰老和与年龄相关疾病成因的氧化应激之间存在权衡。应激反应和衰老通过对氧化还原敏感的转录因子(如核因子κB)相联系。衰老是细胞内氧化应激上升的结果,而非时间的函数,但这种关系被掩盖了,因为线粒体的自由基泄漏也往往随年龄增长而增加。线粒体泄漏产生一种遗传反应,类似于感染后的反应,但由于线粒体泄漏是持续的,基因表达的变化是持久的,导致了老年的慢性炎症特征。因此,与年龄相关的疾病是我们为应激基因表达的氧化还原控制所付出的代价。由于在年轻时有利于应激反应的选择压力强于在生殖能力下降后对退行性疾病的惩罚压力,我们可能对“淹没”氧化还原开关的抗氧化剂补充剂具有内稳态抗性。此外,由于基因选择主要发生在年轻时的还原性内稳态环境中,与年龄相关疾病相关的等位基因并非天生具有损害性(它们不会随着时间的推移不可避免地表达负面影响),而只是在老年的氧化条件下效果较差。除非能通过生理手段控制氧化应激,从而改变潜在数百个基因的活性和功能,否则针对与年龄相关疾病的基因疗法不太可能成功。